Medtronic Plc
Latest Medtronic Plc News and Updates
Company & Industry OverviewsWhat’s behind Medtronic’s Accelerating Margin Expansion?
In fiscal 1Q18, Medtronic (MDT) reported ~26.9% of operating margin on a constant currency basis. This represented year-over-year growth of ~50 basis points. Company & Industry OverviewsIntuitive Surgical Plans to Expand in Europe and Asia
Although Intuitive Surgical leads the surgical robotics market, there are competitive threats from other major players in the market. Company & Industry OverviewsDivestiture of a Part of Medtronic’s PMR Business to Cardinal Health
Medtronics’ MITG (Minimally Invasive Therapies Group) business is expected to grow 3.5%–4.5%. Company & Industry OverviewsHow Medtronic Is Delivering on Its Covidien Synergies
In January 2015, Medtronic (MDT) acquired Covidien for ~$43 billion in cash and MDT stock in a tax inversion deal. Company & Industry OverviewsMedtronic’s Emerging Market Position and Opportunities for Fiscal 2018
Medtronic (MDT) registered revenues of ~$1.0 billion revenues from emerging markets in fiscal 1Q18, which represents YoY (year-over-year) sales growth of ~11% in that market. Company & Industry OverviewsStryker Stock Falls Due to the Impact of the Sage Products Recall
On August 23, Stryker (SYK) announced a voluntary product recall of specific lots of oral care products that form part of the company’s Sage business unit. Company & Industry OverviewsWhat Zimmer Biomet’s Leadership Transition Could Mean for Its Core Growth Strategy
In July 2017, David Dvorak stepped down as chief executive officer and president of Zimmer Biomet (ZBH) and resigned from its board of directors. Company & Industry OverviewsHow Medtronic Is Accelerating Its Economic Value Growth Strategy
Medtronic’s (MDT) Hospital Solutions segment registered double-digit growth in fiscal 1Q18. Company & Industry OverviewsHow Is Becton Dickinson Progressing with Emerging Market Growth?
Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17. Company & Industry OverviewsSanofi’s General Medicines and Consumer Healthcare in 2Q17
General Medicines Sanofi’s (SNY) generic business contributed ~5.1% of its total revenue in 2Q17. The business reported revenue of 442 million euros in 2Q17, an 8% decrease from 2Q16. Revenue fell due to lower sales in US markets, European markets, and emerging markets. This fall was partially offset by the growth in the rest of […] Company & Industry OverviewsEdwards Lifesciences Focuses on Indication Expansion of SAPIEN 3 in 2017
To further expand the label of its transcatheter heart valve (or THV), SAPIEN 3, Edwards Lifesciences (EW) is currently involved in enrolling patients in its EARLY-TAVR trial. Company & Industry OverviewsEdwards Lifesciences’ Mitral Regurgitation Segment
To diversify its focus beyond aortic structural heart conditions, Edwards Lifesciences (EW) acquired CardiAQ Valve Technologies in August 2015. Company & Industry OverviewsEdwards Lifesciences Focuses on Launch of SAPIEN 3 Ultra and CENTERA Valves
Edwards Lifesciences’ (EW) SAPIEN 3 Ultra system is a next-generation platform, with expandable Axela sheath technology and on-balloon delivery design. Company & Industry OverviewsEdwards Lifesciences: Focused on Inspiris Resilia and Konect
To extend the durability of the Inspiris Resilia surgical aortic valve, Edwards Lifesciences (EW) has incorporated a new tissue platform, Resilia tissue. Company & Industry OverviewsCan Edwards Intuity Elite Boost Edwards Lifesciences’ Revenues?
With the Edwards Intuity Elite valve system, Edwards Lifesciences aims to offer a minimally invasive therapy to complex aortic stenosis patients. Company & Industry OverviewsTranscatheter Heart Valve Therapy: Growth Driver for Edwards Lifesciences
In 2Q17, Edwards Lifesciences’ (EW) Transcatheter Heart Valve Therapy segment reported revenues close to $316 million, which represents year-over-year growth of ~28%. Company & Industry OverviewsWhere Abiomed Plans to Expand Impella CP’s Label
About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems. Company & Industry OverviewsWhy Abiomed Expects to Benefit from Impella in Cardiogenic Shock
On March 23, 2015, the FDA approved Abiomed’s Impella 2.5 heart pump as a temporary ventricular support device. Earnings ReportJohnson & Johnson: Medical Devices in 2Q17
Medical devices segment Johnson & Johnson’s (JNJ) medical devices segment grew ~4.9% to ~$6.7 billion for 2Q17, compared with $6.4 billion in 2Q16. This rise included an operational increase of 5.9%, and was offset by a 1% impact of foreign exchange. Cardiovascular care franchise Cardiovascular care franchise sales rose 11.3% to $523 million for 2Q17. This […] Company & Industry OverviewsBehind Abiomed’s Plans to Create a Greater Awareness of Impella
To target patients across communities, Abiomed (ABMD) has been developing a hub-and-spoke model with hospitals. Company & Industry OverviewsAbiomed Aims to Expand Impella RP’s Penetration Going Forward
In March 2017, Abiomed (ABMD) submitted premarket approval (or PMA) to the FDA for its Impella RP device far ahead of schedule. Earnings ReportBehind the Major Drivers of JNJ’s Medical Device Growth
Johnson & Johnson (JNJ) reported Medical Devices segment sales of ~$6.7 billion in 2Q17, compared with $6.4 billion in 2Q16. Company & Industry OverviewsHow Stryker Plans to Capture the International Markets
Most of Stryker’s emerging market sales are from China. However, Europe and emerging markets sales have witnessed high growth in recent quarters. Company & Industry OverviewsMedtronic’s Agreement Will Expand the Use of Its Tyrx Envelopes
Medtronic’s (MDT) Tyrx envelope is an antibacterial and fully-absorbable device that helps prevent surgical site infections. Company & Industry OverviewsMedtronic Received Health Canada License for SureTune3
On June 6, 2017, Medtronic (MDT) received the Health Canada license for its SureTune3 software for DBS (deep brain stimulation) therapy. Company & Industry OverviewsUnderstanding Thermo Fisher’s Capital Deployment Strategy
Thermo Fisher Scientific expects to deploy 60%–75% of its capital toward M&As (mergers and acquisitions). Company & Industry OverviewsZimmer Biomet’s Capital Allocation Strategy to Create Value
In February 2016, Zimmer Biomet authorized up to $1.0 billion of the company’s common stock for share repurchases, all of which remains authorized to date. Company & Industry OverviewsHow Long Can Thermo Fisher Scientific’s Asia-Pacific Growth Momentum Last?
Thermo Fisher Scientific (TMO) has a presence around the globe, but around 80% of its revenues are generated from developed markets. Macroeconomic AnalysisIs Medical Technology Driving the US Healthcare Industry?
The US medical device industry is a global leader. Its market was valued at ~$140 billion for 2016. It represents ~45% of the global market. Company & Industry OverviewsA Look at BD’s Deal Rationale in Its C.R. Bard Acquisition
BD’s acquisition of C.R. Bard is aimed at providing a comprehensive product portfolio to customers at more reasonable costs and enhanced efficiency. Company & Industry OverviewsThese Pfizer Products Saw Declining Revenues in 2016
The overall share of revenues for the Essential Health Products business fell marginally to 44.7% of the total revenues for 2016 from 45.2% of the total revenues for 2015. Company & Industry OverviewsAnalyzing the BD Medical Segment’s Product Pipeline
Becton, Dickinson and Company (BDX) generates ~$1 billion from its Infection Prevention business. Company & Industry OverviewsInside Edwards Lifesciences’ THV Product Pipeline and Future Growth Estimates
Edwards Lifesciences (EW) has a robust product pipeline in its THV (transcatheter heart valve) segment, with Sapien 3 as the segment’s leading product. Earnings ReportMedtronic’s RTG Sales in Fiscal 2Q17: The Brain and Restorative Therapies Story
Of Medtronic’s ~$7.3 billion in worldwide revenue in fiscal 2Q17, ~$1.8 billion came from its RTG segment, representing ~25% of the company total. Earnings ReportHere’s What’s Driving Medtronic’s MITG Segment
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.5 billion came from Medtronic’s MITG segment, representing ~34% of the company’s total revenues. Company & Industry OverviewsHow Stryker Plans to Leverage the Under-Tapped Europe Opportunity
Europe represents a potential growth opportunity for Stryker, as the company currently has a low market share in Europe compared to other developed markets. Company & Industry OverviewsA Look at Zimmer Biomet’s Latest Valuation
After the release of its 2Q16 earnings results on July 28, 2016, Zimmer Biomet Holdings (ZBH) was trading at a forward price-to-earnings multiple in the range of 15.5x–16.2x. Company & Industry OverviewsMedtronic’s Minimally Invasive Therapies Group: Major Drivers
Medtronic plans to launch more than 80 products over the next three years. Company & Industry OverviewsA Look at Medtronic’s Geographic Strategy in 2016
Globalization is one of Medtronic’s (MDT) key growth strategies. Company & Industry OverviewsWhat Drives Medtronic’s Restorative Therapies Group’s Growth?
Medtronic’s (MDT) Restorative Therapies Group (or RTG) segment, formed around seven years ago, has a strong market position today. Company & Industry OverviewsWhat Drives Medtronic’s Cardiac Vascular Group’s Revenues?
Medtronic’s (MDT) Cardiac and Vascular Group (or CVG) is its largest segment. Company & Industry OverviewsWhat’s the Verdict on Becton Dickinson’s Strategic Portfolio Review?
Becton Dickinson (BDX) completed its annual strategic review of its portfolio, which was initiated after the acquisition of CareFusion. Company & Industry OverviewsWhat Does Intuitive Surgical’s Business Model Look Like?
Intuitive Surgical (ISRG) defines its business model as a “razor/razor blade” model. What does this mean? Company & Industry OverviewsExploring Intuitive Surgical’s Sales Model
Intuitive Surgical follows a diversified sales strategy and doesn’t generate more than 10% of its revenue through any one customer. Company & Industry OverviewsAnalyzing Intuitive Surgical’s R&D Strategy and Innovations
Intuitive Surgical is continuously enhancing its product offerings, enabling more efficient procedures through internal research and development (or R&D). Company & Industry OverviewsA Closer Look at Intuitive Surgical’s Business Strategy
Intuitive Surgical aims to include a larger patient population under its MIS treatments and to provide better surgery outcomes and lower recovery times. Company & Industry OverviewsHow Is Boston Scientific’s Geographic Strategy Driving Growth?
Boston Scientific has strategically expanded in these geographies through organic as well as inorganic strategies. Company & Industry OverviewsThe Business Strategies Driving Boston Scientific’s Growth
Boston Scientific registered emerging market sales growth of approximately 13% in 2015, representing a steady growth in international markets. Company & Industry OverviewsUnderstanding Boston Scientific’s MedSurg Segment
Boston Scientific’s (BSX) MedSurg segment contributes around 33% to the company’s total revenues and is the company’s second-largest segment. Company & Industry OverviewsA Brief Look at Boston Scientific’s Business Model
Boston Scientific’s (BSX) Cardiovascular segment consists of minimally invasive technologies to treat patients with a wide range of heart and vascular diseases. It is BSX’s largest business segment and generated ~39% of the company’s total revenues in 2015.